EGMN -- Daily fondaparinux significantly reduced the relative risk of symptomatic thromboembolic complications or death by 85% – without increasing the incidence of bleeding – in a study of some 3,000 patients with acute symptomatic lower-limb superficial-vein thrombosis.
